The Online Investor
EPIRUS Biopharmaceuticals Inc (ZLCS)

Zalicus is a biopharmaceutical company engaged in developing drug candidates with a focus on the treatment of pain. Co.'s primary product candidate is Z160, an oral N-type calcium channel blocker that Co. is seeking to develop for the treatment of chronic pain. Co.'s other product candidate is Z944, an oral T-type calcium channel blocker that Co. is seeking to develop for the treatment of pain indications. In addition, Co. is performing discovery research and preclinical development activities on its proprietary selective ion channel modulators targeting the Nav1.7 sodium channel as well as N-type and T-type calcium channels, as part of a research collaboration with Hydra Biosciences, Inc.
Company Name: 
EPIRUS Biopharmaceuticals Inc
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree ZLCS Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

EPIRUS Biopharmaceuticals Inc (ZLCS) Page | The Online Investor Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.